BIG
AUTL

Brooklyn Investment Group’s Autolus Therapeutics AUTL Stock Holding History

Brooklyn Investment Group’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-377
Closed -$886 – 2775
2024
Q4 		$886 Buy
+377
New +$1.27K ﹤0.01% 1620

Other funds holding AUTL

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Brooklyn Investment Group's AUTL Position: Q1 2025 in Review

Brooklyn Investment Group sold out of Autolus Therapeutics (AUTL) in Q1 2025, closing a stake of 377 shares — an estimated $886 sold.

Brooklyn Investment Group first reported a position in AUTL in Q4 2024 and held it in 1 quarter. The position peaked at $886 in Q4 2024. 95 funds tracked by Wall St. Rank hold AUTL as of Q1 2025.

  • Brooklyn Investment Group reported no remaining Autolus Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Brooklyn Investment Group sold 377 Autolus Therapeutics shares in Q1 2025, an estimated $886.
  • Brooklyn Investment Group first reported a position in Autolus Therapeutics in Q4 2024 and held it in 1 quarter.
  • Brooklyn Investment Group's Autolus Therapeutics position peaked at $886 in Q4 2024.
  • 95 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q1 2025.

Based on Brooklyn Investment Group's 13F filing for Q1 2025, filed 13 May 2025.